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Small cell carcinoma (SCC) of the prostate is a high-grade malignant neoplasm with neuroendocrine
differentiation and accounts for only 0.5e2% of all prostate cancers. From 2005 to 2010, there were a total
of three cases of SCC at our hospital. The disease onset age was 61, 74, and 84 years, respectively. Initial
presentations include urinary difﬁculty, bone pain, and gross hematuria. One patient had mixed tumors
of both SCC and adenocarcinoma, and two had prior adenocarcinomas that recurred as SCC. The diag-
nosis of SCC was all made via transurethral resection. Two patients died of their diseases 7 and 15
months after diagnosis, and one survived for more than 65 months. The serum prostate speciﬁc antigen
(PSA) was 1660 ng/mL, 72.8 ng/mL, and 35.7 ng/mL before deﬁnitive diagnosis. Notably, the only sur-
viving patient was diagnosed with SCC after the transurethral resection of prostate because of the
presence of lower urinary tract symptoms. The serum PSA prior to the operation was 0.11 ng/mL, and he
received chemotherapy with 5 courses of cisplatin and VP-16. Palliative transurethral resection of the
prostate (TURP) not only solved the obstructive symptoms of voiding but helped in removing the
prostate tissue, which might have the SCC component in patients with prostate adenocarcinoma under
androgen deprivation therapy.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Small cell carcinoma (SCC) of prostate is a high-grade malignant
neoplasmwith neuroendocrine differentiation. It accounts for only
0.5e2% of all prostate cancer cases. Unlike patients with prostate
adenocarcinoma, patients with prostate SCC usually have no
elevated serum PSA. Only half of the patients presented with pure
SCC at the initial diagnosis, one-quarter of the cases demonstrate a
combination of adenocarcinoma and SCC, and the other 25% are
presented with adenocarcinoma under hormone therapy with
disease recurred as SCC.1 Herein we present three cases of prostate
SCC treated in our hospital from 2005 to 2010.
2. Case reports
2.1. Case 1
A 61-year-old man had right renal stones and received extra-
corporeal shock wave lithotripsy (ESWL) twice at another hospital.tment of Surgery, Taipei Vet-
, Taipei 11217, Taiwan, ROC.
ang).
ciation. Published by Elsevier TaiwSubsequently, he developed pain at his thoracic cage and bilateral
inguinal areas and abdominal computed tomography (CT) scan
revealed advanced prostate cancer with enlarged lymph nodes over
the celiac axis, portocaval, aortocaval, retrocaval, paraaortic, bilat-
eral common iliac, internal iliac, external iliac, right obturator, and
bilateral inguinal regions (Fig. 1). Whole body bone scan conﬁrmed
the ﬁndings of bone metastases. Clinical stage was T4N2M1. Serum
PSA levels were 1660 ng/mL. The prostate biopsy revealed a Glea-
son 5þ5 adenocarcinoma (Fig. 2A). Androgen blockade with
gosereline and ﬂutamide were given, and his PSA dropped to the
nadir 42.06 ng/mL in 2 months. However, it rose to 444 ng/mL
3 months later. Owing to an episode of hematuria, he received a
cystoscopy and was treated with the palliative TURP. The pathology
reported SCC (Fig. 2BeD). However, he failed to follow up and died
7 months after the diagnosis of SCC.2.2. Case 2
A 59-year-old man was diagnosed adenocarcinoma of the
prostate at another hospital with an initial PSA of 72.81 ng/mL. The
tumor was Gleason 4þ4, and the clinical staging was T3aN1M0.
Combined androgen blockade with triptoreline and bicalutamide
were used to control the disease. The PSA nadir was 0.00 ng/mLan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Computed tomography scan. (A) Enlarged prostate gland with irregular soft tissue density and direct invasion of bile. Seminal vesicles and bladder base. (B) Multiple enlarged
lymph nodes over the celiac axis, portocaval, aortocaval, retrocaval, and paraaortic regions.
I.-S. Huang et al. / Urological Science 24 (2013) 131e13513212 months after the commencement of medication. Owing to his
persistent voiding symptoms, he received holmium laser ablation
of prostate 21 months later. Pathology of the specimen disclosed
SCC, which were immunohistochemically positive for cytokeratin
(CKER), CD 56, chromogranin, and synaptophysin (Figs. 3 and 4Ae
D). The serum PSA level prior to the operation was 0.11 ng/mL. The
CT images disclosed the presence of a pair of soft tissue lesions and
an enlarged lymph node in the pelvic cavity adjacent to left obtu-
rator muscle (Fig. 5). Owing to the impression of disease progres-
sion, he received concurrent chemoradiation therapy (CCRT) with
cisplatin and etoposide for ﬁve cycles. The clinical condition was
stable after CCRT and his latest PSA was 0.40 ng/mL.
2.3. Case 3
An 84-year-oldmanwith hypertension, type 2 diabetesmellitus,
and arrhythmia came to our hospital because of acute urinaryFig. 2. (A) Adenocarcinoma, Gleason grade 5þ5 (H&E stain, 200). (B) This small cell carc
nuclei with nuclear crowding and overlapping (H&E stain, 400). (C) Diffusely immun
H&E ¼ Hematoxylin and eosin.retention. The initial PSA was 35.7 ng/mL. The transurethral
resection of prostate showed the ﬁndings of combined adenocar-
cinoma (Gleason 4þ4) and SCC (Fig. 6). His clinical stage was
T4N0M0 (Fig. 7). Cyproterone acetate and CCRT (with cisplatin and
etoposide 3 cycles) were given. The PSA nadir was 0.17 ng/mL at 3
months after the treatment. However, he developed bilateral lower
leg weakness 1 year later. Brain CT showed evidence of tumor
metastasis to brain, which was later conﬁrmed as metastatic SCC
via biopsy. Unfortunately, the disease progressed to lungmetastasis
and the patient died of the disease.
The demographic data and treatment results of the three pa-
tients are summarized in Table 1.
3. Discussion
The literature from western countries concluded that the pros-
tate is the most common extrapulmonary organ to have SCC. Moreinoma is composed of sheets of small cells with scant cytoplasm and hyperchromatic
oreactive with CD56 stain. (D) Diffusely immunoreactive with synaptophysin stain.
Fig. 3. Section shows prostate tissue inﬁltrated with solid aggregates of small tumor
cells, which have scanty cytoplasm and a highly hyperchromatic, oval to elongated
nucleus (hematoxylin and eosin stain, 400).
Fig. 5. Enlarged lymph node in the left external iliac region encompassing the left
external iliac artery.
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static disease, and 39.5% presented as local/regional disease. The
observed survival rates 12, 24, 36, 48, and 60 months after the
diagnosis of prostate SCC were 47.9%, 27.5%, 19%, 17%, and 14.3%,
respectively.2 Data from Taiwan indicated that lung was the most
common (89.2%) location of SCC. It is followed by the esophagus
(1.8%), urinary bladder (1.6%), uterine cervix (1.5%), colorectum
(1.4%), skin (1.0%), stomach (0.9%), head and neck (0.7%), prostate
(0.3%), and small intestine (0.1%).
Abbas et al3 reported 130 cases of prostate SCC, 67 (52%) were
pure SCCs, and 52 (40%) were associated with adenocarcinoma.
Forty-three (43%) patients were initially diagnosed as having
prostate adenocarcinoma with no small cell component and later
developed into prostate SCC.Fig. 4. Immunohistochemical features of small cell carcinoma positive forGenerally, the median survival time was 8 months for all SCC
patients in Taiwan.4 For prostate SCC, the treatment is different
from that of the prostate adenocarcinoma. The treatment of SCC is
mainly chemotherapy. The presenting symptoms include those
speciﬁc for lower urinary tract symptoms (frequency, nocturia,
urinary retention, urinary obstruction) and nonspeciﬁc constitu-
tional symptoms (poor appetite, weight loss). In our series, the
three patients reported inguinal pain, urinary retention, and uri-
nary difﬁculty.
The origin of prostate SCC is unclear. It has been hypothesized
that prostate SCC arises from the neural crest line/amine precursor
uptake decarboxylation (APUD) cell system, which is then distrib-
uted throughout the prostate and urethra. They are capable ofcytokeratin (A), CD56 (B), chromogranin (C), and synaptophysin (D).
Fig. 6. (A) Composition of SCC (right upper quadrant) and Gleason grade 4þ4 adenocarcinoma. (B) SCC showed immunoreaction with chromogranin A (right), whereas the
adenocarcinoma component is nonreactive with chromogranin A stain (left). (C) SCC showed immunoreaction with CD56 (upper), whereas the adenocarcinoma component is
nonreactive with CD56 stain (lower). (D) SCC showed immunoreaction with synaptophysin (right), whereas the adenocarcinoma component is nonreactive with the synaptophysin
stain (left). (AeD) Hematoxylin and eosin stain, 400. SCC ¼ small cell carcinoma.
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B, adrenocorticotropic hormones, calcitonin, parathyroid hormone-
related protein, thyroid-stimulating hormone, and somatostatin.
Prostatic endocrine cells are also believed to regulate cellular
growth and differentiation via autocrine, paracrine, or endocrine
and neurocrine mechanisms.5 Another theory, which is based upon
the ﬁnding of coexistent adenocarcinoma and SCC, postulates that
SCC arises from the dedifferentiated prostatic adenocarcinoma.6
The latest and currently the most accepted theory suggests that
SCC has its own stem cell origin and is not derived from dediffer-
entiated adenocarcinoma or from benign neuroendocrine cells of
the prostatic epithelium. This hypothesis is based on the ﬁnding
that the tumor cells lack typical immunohistologic characteristics
of prostatic epithelial cells (PSA expression and androgen receptorFig. 7. The prostate is enlarged withpositivity) and their much elevated index of MIB-1 than that of the
dedifferentiated adenocarcinomas.7
The proportion of neuroendocrine differentiation in prostatic
carcinoma varied from 10% to 100%, and androgen ablation therapy
was considered a contributing factor in increasing the proportion of
neuroendocrine differentiated malignant cells over time.8 Whether
there is prognostic value in the degree of neuroendocrine differ-
entiation is still a topic of debate.
The SCC can be divided into two types: “oat cell” type and “in-
termediate” cell type. The “oat cell” type is characterized by cells
only slightly larger than lymphocytes with scant cytoplasm,
hyperchromatic nuclei with salt, and pepper chromatin without
prominent nucleoli, whereas in the “intermediate” cell type, the
tumor cells have more abundant cytoplasm and visible nucleoli.1heterogeneous enhancement.
Table 1
Clinical and demographic characteristics of the patients with prostate small cell carcinoma.







Initial Nadir SCC occurrence Final
1 61 AdenoCa cT4N2M1 5þ5 5 LN, Bone Dead (7) 1660 42.1 444 1876 Bicalutamide, goserelin, TURP
2 62 AdenoCa cT3aN1M0 4þ4 34 LN Alive (65) 72.8 0.00 0.11 0.40 Bicalutamide, decapeptyl,
TURP, CCRT, cisplatin, etoposide
3 84 SCC, AdenoCa cT4N0M0 4þ4 Initial Brain, lung Dead (30) 35.7 0.17 d 0.22 CCRT, cisplatin, etoposide
CCRT ¼ concurrent chemoradiation therapy; LN ¼ lymph node; SCC ¼ small cell carcinoma; TURP ¼ transurethral resection of prostate.
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adenocarcinoma cases with immunohistochemical stain. Results
showed neuroendocrine markers varied in expression with
chromogranin A showing strong expression (61%) in prostate SCC
only. Synaptophysin is positive in most prostate SCC (89%) and
also positive in some Gleason pattern 5b prostate adenocarci-
noma (40%). The most speciﬁc neuroendocrine markers were PSA,
TTF-1 and CD56 in differentiating prostate SCC and Gleason
pattern 5b prostate adenocarcinoma.
Regarding the treatment, two patients in this series received
CCRT with etoposide and cisplatin. The only patient who had sur-
vived over 65months also received further treatment with cisplatin
and etoposide. He achieved complete remission 10 months after
the treatment. We believe that his favorable outcome is because of
the early detection of malignant neuroendocrine transformation by
transurethral resection.
The combination of platinum and etoposide is the most widely
used standard chemotherapeutic regimen for pulmonary SCC. The
prostatic SCC was assumed to respond to this chemotherapy.
Recently, favorable responses were reported using gemcitabine,
docetaxel, and carboplatin.10 Primary surgery, including transure-
thral resection and radical prostatectomy, was the only indepen-
dent parameter found to predict outcome of prostatic SCC in one
retrospective study.11 In the review of 241 cases with prostatic SCC,
the age at diagnosis and the stage and grade of associated prostate
adenocarcinoma were signiﬁcant predictors.2
Palliative TURP might not only solve the obstructive symptoms
of voiding but also obtain prostate tissue for examination. Among
them, there may be an SCC component in patients with prostate
adenocarcinoma under androgen deprivation therapy. Prostate SCC
is a distinct pathological entity, and treatment plan varies from
prostate adenocarcinoma, in which prostate SCC requires further
chemotherapy for disease control.Conﬂicts of interest statement
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